Drug Combination Details
| General Information of the Combination (ID: C91592) | |||||
|---|---|---|---|---|---|
| Name | Luteolin NP Info | + | Gemcitabine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Pancreatic cancer
[ICD-11: 2C10]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | GSK-3B | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | KRAS | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
| In-vitro Model | BxPC-3 | CVCL_0186 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
| In-vivo Model | Male athymic nude mice were inoculated with BxPC-3 cells (1*106 cells/mouse) cells. | |||||
| Experimental
Result(s) |
Combination of luteolin and gemcitabine promoted apoptotic cell death in pancreatic tumor cells in vivo through inhibition of the K-ras/GSK-3beta/NF-kappaB signaling pathway, leading to a reduction in the Bcl-2/Bax ratio, release of cytochrome c, and activation of caspase 3. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Luteolin and Gemcitabine Protect Against Pancreatic Cancer in an Orthotopic Mouse Model. Pancreas. 2015 Jan;44(1):144-51. | |||
